The Niche medical writing team was involved in drafting clinical study protocols, providing a succinct but bespoke service to help support efforts in progressing an early-phase clinical program, with a tailored focus on the United States Food and Drug Administration. Niche medical writers also provided writing and editorial services for the creation and publishing of a clinical research manuscript.
The services required were targeted at providing comprehensive clinical study protocols and a manuscript with quick turnaround times to provide a solid framework to kickstart progress on a successful early-phase clinical development pathway. Additional ad hoc work helped bolster the clinical research package.
Following support by the Niche team, Lefamulin the drug for which Niche contributed to the writing of study protocols, saw successful CTA results and has since progressed through the clinical development pathway and was successfully approved by the FDA, EMA and Health Canada. Additionally, the manuscript was published in The Journal of Antimicrobial Chemotherapy.
"I continue to use Niche Science and Technology in my present endeavours, where they work seamlessly with my staff to prepare various clinical study documentation and submissions."
Niche began work with Nabriva in 2010, writing key documents and standard operating procedures for their quality management system. This was followed by providing support in delivering regulatory writing for BC-3205, a novel representative of pleuromutilins, a new class of antibiotics for human use, and BC-3781, a semi-synthetic pleuromutilin. The Niche were involved in wring a series of protocols, CSRs, IMPDs and Investigator Brochure updates. As these assets matured the Niche became involved in writing manuscripts for submissions to scientific journals as well as coordinating the manuscript submissions and responses to reviewers.
Niche delivered rigorous QC and medical writing support across Adaptimmune's full suite of regulatory documents, keeping.
read moreFrom Phase 2 through to the global Phase 3 HEAL-MI trial, Niche has been Recardio's trusted writing and regulatory.
read moreWhen stalled regulatory documentation threatened to derail their neurological programme, Cleothena turned to Niche —.
read moreNiche provided Astex with expert regulatory writing across their oncology pipeline, delivering clinical protocols, study.
read moreNiche built and coordinated the full communications strategy for this 20-institution European initiative, turning.
read moreOver a decade and 20+ guidelines later, Niche remains the BSH's trusted partner for raising haematology care standards.
read morePutting patients first, Niche supported ViiV Healthcare's global HIV outreach programmes with medical writing,.
read moreAt the height of the pandemic, Niche's rapid manuscript writing helped Synairgen publish their landmark interferon beta.
read moreFor over a decade, Assign DMB relied on Niche as their embedded writing partner, seamlessly converting statistical.
read moreA trusted writing partner to this Belfast-based early-phase CRO for over a decade, Niche turned BioKinetic Europe's.
read moreNiche served as the English-language regulatory writing backbone for this Nordic consultancy, producing IBs, IMPDs and.
read moreGet our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
